Cardiac immune-related adverse events: an immune-cardio-oncology puzzle
- PMID: 34383998
- DOI: 10.1002/ejhf.2329
Cardiac immune-related adverse events: an immune-cardio-oncology puzzle
Comment on
-
Cardiotoxicity associated with immune checkpoint inhibitor therapy: a meta-analysis.Eur J Heart Fail. 2021 Oct;23(10):1739-1747. doi: 10.1002/ejhf.2289. Epub 2021 Jul 29. Eur J Heart Fail. 2021. PMID: 34196077
References
-
- Robert C. A decade of immune-checkpoint inhibitors in cancer therapy. Nat Commun 2020;11:3801.
-
- Marin-Acevedo JA, Kimbrough EO, Lou Y. Next generation of immune checkpoint inhibitors and beyond. J Hematol Oncol 2021;14:45.
-
- Ramos-Casals M, Brahmer JR, Callahan MK, Flores-Chávez A, Keegan N, Khamashta MA, Lambotte O, Mariette X, Prat A, Suárez-Almazor ME. Immune-related adverse events of checkpoint inhibitors. Nat Rev Dis Primers 2020;6:38.
-
- Palaskas N, Lopez-Mattei J, Durand JB, Iliescu C, Deswal A. Immune checkpoint inhibitor myocarditis: pathophysiological characteristics, diagnosis, and treatment. J Am Heart Assoc 2020;9:e013757.
-
- Rubio-Infante N, Ramírez-Flores YA, Castillo EC, Lozano O, García-Rivas G, Torre-Amione G. Cardiotoxicity associated with immune checkpoint inhibitor therapy: a meta-analysis. Eur J Heart Fail 2021;23:1739-1747.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
